Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2015

 

 

GlycoMimetics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36177   06-1686563

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

9708 Medical Center Drive

Rockville, MD 20850

(Address of principal executive offices, including zip code)

(240) 243-1201

(Registrant’s telephone number, including area code)

401 Professional Drive, Suite 250

Gaithersburg, MD 20879

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On July 15, 2015, GlycoMimetics, Inc. (the “Company”) held its 2015 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 15, 2015. Of the 19,017,133 shares outstanding as of the record date, 17,053,758 shares, or 89.7%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of two nominees to serve as directors until the 2018 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

 

Name

   Votes For      Votes Withheld  

Rachel K. King

     12,234,400         476,828   

Michael A. Henos

     12,209,580         501,648   

Broker Non-Votes: 4,342,530.

Both nominees were elected.

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015. The votes were cast as follows:

 

     Votes For      Votes Against      Abstained  

Ratification of appointment of Ernst & Young

     17,048,355         5,313         90   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

GLYCOMIMETICS, INC.
By:

/s/ Brian M. Hahn

Date: July 20, 2015

Brian M. Hahn

Chief Financial Officer